Observational studyIntensive care medicine2024
Reactivation of Epstein-Barr virus among intensive care patients: a prospective observational study.
Observational study in Intensive care medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Viral Reactivation in Immunocompetent Critically Ill Patients.Microorganisms · 2026Review
- The Acute Respiratory Distress Syndrome (ARDS): epidemiology, etiology, molecular mechanisms, diagnosis and therapeutic strategies.Molecular biomedicine · 2026Review
- The Current Status ofPathogens (Basel, Switzerland) · 2026Article
- EBV reactivation and immunoparalysis indicate a harmful immune endotype in sepsis.Critical care (London, England) · 2026Article
- Investigation of genetic and lifestyle risk factors associated with Epstein-Barr virus reactivation in the Thai population.Biomedical reports · 2026Article
- Higher prevalence of cytomegalovirus and Epstein-Barr virus in acute-on-chronic liver failure.JHEP reports : innovation in hepatology · 2026Article
- Characterization of multiple herpes viremia via next-generation sequencing in patients with lower respiratory tract infections: a retrospective cohort study.BMC infectious diseases · 2026Article
- Clinical and biological features of CMV reactivation in ARDS: a prospective cohort study.Critical care (London, England) · 2026Article
- Blood mNGS-Detected Epstein-Barr Virus in ICU Patients with Pneumonia: Associations with Disease Severity Markers and Inflammatory Burden.Infection and drug resistance · 2026Article
- Article
- Guillain-Barré syndrome with T-cell receptor gene clonal rearrangement following COVID-19 vaccination: a case report.Clinical and experimental vaccine research · 2025Article
- The Landscape of lower respiratory tract herpesviruses in severe pneumonia patients: a multicenter, retrospective study with prospective validation.Critical care (London, England) · 2025Article
- Cytomegalovirus Blood DNAemia in Patients with Severe SARS-CoV-2 Pneumonia.Infectious disease reports · 2025Article
- Gastrointestinal dysfunction in aneurysmal subarachnoid hemorrhage: prevalence, clinical correlates, and prognostic implications from a 15-year ICU cohort study.Frontiers in neurology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeHerpesvirus reactivation has been documented among patients in the intensive care unit (ICU) and is associated with increased morbidity and mortality, particularly for cytomegalovirus (CMV). Epstein-Barr virus (EBV) has been poorly studied despite >95% of the population being seropositive. Our preliminary study suggested an association between EBV reactivation and increased morbidity and mortality. This study aimed to investigate this association among patients admitted to the ICU.
methodsIn this multicenter prospective study, polymerase chain reaction was performed to quantify EBV in patients upon ICU admission and then twice a week during their stay. Follow-up was 90 days.
resultsThe study included 129 patients; 70 (54.3%) had EBV reactivation. On day 90, there was no difference in mortality rates between patients with and without reactivation (25.7% vs 15.3%, p = 0.22). Patients with EBV reactivation at admission had increased mortality compared with those without reactivation and those with later reactivation. EBV reactivation was associated with increased morbidity. Patients with EBV reactivation had fewer ventilator-free days at day 28 than those without reactivation (18 [1-22] vs. 21 days [5-26], p = 0.037) and a higher incidence of acute respiratory distress syndrome (34.3% vs. 17%, p = 0.04), infections (92.9% vs. 78%, p = 0.03), and septic shock (58.6% vs. 32.2%, p = 0.004). More patients with EBV reactivation required renal replacement therapy (30% vs. 11.9%, p = 0.02). EBV reactivation was also associated with a more inflammatory immune profile.
conclusionWhile EBV reactivation was not associated with increased 90-day mortality, it was associated with significantly increased morbidity.
Indexed as
Identifiers
38436725What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.